secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORASURE TECHNOLOGIES INC (OSUR)
CIK:        0001116463
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001116463-26-000002
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OraSure submits two FDA applications for rapid CT/NG self-test and at-home urine collection device
--------------------------------------------------------------------------------

- Submitted two FDA 510(k) applications: one for a rapid molecular self-test for Chlamydia and Gonorrhea (CT/NG) and one for the Colli-Pee at-home urine collection device for STI indications.
- Rapid CT/NG self-test is designed to deliver results in approximately 30 minutes in a disposable, over-the-counter format.
- Colli-Pee device is intended for at-home urine collection, including for multiple STI indications.
- No timeline for FDA clearance; approval would open new OTC market for OraSure in sexual health diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1116463/000111646326000002/0001116463-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1116463/000111646326000002/osur-20260105.htm
  HTML page:      https://secwatch.observer/filing/0001116463-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer